GLOBAL REGISTRATION TRIAL OF EFFICACY AND SAFETY OF CTL019 IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): UPDATE TO THE INTERIM ANALYSIS
EHA Learning Center, Stephan A. Grupp, 181763
SERIAL SEQUENCING REVEALS CLONAL ORIGINS AND STRATEGIES FOR EARLY DETECTION OF POST-ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) RELAPSE IN ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Taehyung Kim, 181778
PHASE 3 ELOQUENT-2 STUDY: EXTENDED 4-YEAR FOLLOW-UP OF ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE VS LENALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Meletios A Dimopoulos, 181743
CYTOGENETIC COMPLEXITY IN CHRONIC LYMPHOCYTIC LEUKEMIA: DEFINITIONS, ASSOCIATIONS WITH OTHER BIOMARKERS AND CLINICAL IMPACT; A RETROSPECTIVE STUDY ON BEHALF OF ERIC
EHA Learning Center, Panagiotis Baliakas, 181748
ENASIDENIB (AG-221) IN MUTANT-IDH2 RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): RESULTS OF A PHASE 1 DOSE-ESCALATION AND EXPANSION STUDY
EHA Learning Center, Eytan M. Stein, 181758
NLPHL - A Forgotten Entity?
EHA Learning Center, Andreas Engert, 184498
Non substitutive therapies for haemophilia
EHA Learning Center, Michael Makris, 184501
Early Phase Clinical Trials In Children: The European Perspective
EHA Learning Center, C.M. Zwaan, 184504
How to present and how to get published: Personal perspective from the Blood Editor-in-chief
EHA Learning Center, Bob Löwenberg, 184507
Double Hit Lymphoma
EHA Learning Center, Martine Chamuleau, 184497
Factor VIII based
EHA Learning Center, Flora Peyvandi, 184500
New drugs for children with hematological malignancies - The US perspective
EHA Learning Center, Peter Adamson, 184503
Introduction: Early Career Committee, Overview on Early Career Session 2 and the two Bite-size classes
EHA Learning Center, Verena I Gaidzik, 184506
AML after 3+7
EHA Learning Center, Norbert Vey, 192903
Prognostic factors in CLL: When, which and how?
EHA Learning Center, Michael Doubek, 192905
Heterogeneity in the making of blood
EHA Learning Center, David Scadden, 184495
Microparticles and Bloodtransfusion
EHA Learning Center, Thierry Burnouf, 192904
Jean Bernard Lifetime Achievement Award: Introduction
EHA Learning Center, Tony Green, 184492
CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE VS CARFILZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE INDUCTION: PLANNED INTERIM ANALYSIS OF THE RANDOMIZED FORTE TRIAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA
EHA Learning Center, Francesca Gay, 181697
HOVON 104; FINAL RESULTS FROM A MULTICENTER, PROSPECTIVE PHASE II STUDY OF BORTEZOMIB BASED INDUCTION TREATMENT FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH DE NOVO AL AMYLOIDOSIS
EHA Learning Center, Monique C. Minnema, 181698
A REVISED STAGING SYSTEM FOR WALDENSTRÖM'S MACROGLOBULINEMIA
EHA Learning Center, Efstathios Kastritis, 181702
SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) TREATED WITH RITUXIMAB (R) MONOTHERAPY: A LONG TERM FOLLOW-UP STUDY ON 104 PATIENTS
EHA Learning Center, Cristina Kalpadaki, 181703
JAK2 V617F HAEMATOPOIETIC CLONES WITH DIFFERENT EXPANSION KINETICS ARE DETECTABLE SEVERAL YEARS PRIOR TO MPN DIAGNOSIS
EHA Learning Center, Thomas McKerrell, 181707
DISRUPTION OF HAEMATOPOIETIC STEM CELL HETEROGENEITY IN A MOUSE MODEL OF MYELOPROLIFERATIVE NEOPLASM
EHA Learning Center, Ruggiero Norfo, 181708
BOSUTINIB VS IMATINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: INITIAL RESULTS FROM THE BFORE TRIAL
EHA Learning Center, Tim H. Brümmendorf, 181712
CHRONIC MYELOID LEUKEMIA PATIENTS WERE NOT DIFFERENT IN MOLECULAR RELAPSE AFTER STOPPING IMATINIB IN MR4 WHETHER RESIDUAL DISEASE WAS DETECTED OR NOT - WHEN ADJUSTING FOR NUMBER OF CONTROL TRANSCRIPTS
EHA Learning Center, Markus Pfirrmann, 181713
PIWIL4 ACTS AS A PIRNA BINDING, EPIGENETICALLY ACTIVE AND GROWTH REGULATORY PROTEIN IN HUMAN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Shiva Bamezai, 181716
METTL3 CONTROLS TRANSLATION OF TARGET MRNAS BY N6 METHYLATION OF ADENOSINE RESIDUES IN THEIR CODING SEQUENCE AND CONSTITUTES A NOVEL THERAPEUTIC VULNERABILITY OF ACUTE MYELOID LEUKAEMIA
EHA Learning Center, Konstantinos Tzelepis, 181717
POSITION OF THE GFI1B ZINC FINGER MUTATION DECOUPLES CD34 EXPRESSION FROM ALPHA-GRANULE DEFICIENCY IN GFI1B-RELATED PLATELET DISORDERS
EHA Learning Center, William STEVENSON, 181721
TREATMENT OF PRIMARY ADULT CHRONIC IMMUNE THROMBOCYTOPENIA (CITP) WITH FOSTAMATINIB, AN ORAL SYK INHIBITOR: RESULTS OF TWO RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDIES
EHA Learning Center, James Bussel, 181722
THE T-CELL LEUKEMIA ASSOCIATED RIBOSOMAL RPL10 R98S MUTATION ENHANCES JAK-STAT SIGNALING
EHA Learning Center, S Vereecke, 181726
NFATC3-PLA2G15 IS A NOVEL INTERGENICALLY SPLICED CHIMERA THAT IS ASSOCIATED WITH AGGRESSIVE T-ACUTE LYMPHOBLASTIC LEUKAEMIA BIOLOGY.
EHA Learning Center, Jonathan Bond, 181727
IMPACT OF A NEW ELECTRONIC ALERT SYSTEM (V2.0) FOR VENOUS THROMBOEMBOLISM PREVENTION IN HOSPITALISED CANCER PATIENTS.
EHA Learning Center, Rocío Figueroa, 181731
IDENTIFICATION OF A NEW AND RELATIVELY FREQUENT SERPINC1 GENE DEFECT CAUSING ANTITHROMBIN DEFICIENCY HARDLY DETECTED BY CURRENT MOLECULAR METHODS: DUPLICATION OF EXON 6.
EHA Learning Center, María Eugenia De La Morena-Barrio, 181732
ABERRANT T CELL RESPONSES IN THE BONE MARROW MICROENVIRONMENT OF PATIENTS WITH POOR GRAFT FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Yuan Kong, 181736
HIGHER FREQUENCY OF SWITCHED MEMORY B CELLS PREDICTS THE INCIDENCE OF CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
EHA Learning Center, Rima Saliba, 181737
CRIZANLIZUMAB, A P-SELECTIN INHIBITOR, INCREASES THE LIKELIHOOD OF NOT EXPERIENCING A SICKLE CELL-RELATED PAIN CRISIS WHILE ON TREATMENT: RESULTS FROM THE PHASE II SUSTAIN STUDY
EHA Learning Center, Abdullah Kutlar, 181741
FREE IRON IN SERA OF PATIENTS WITH SICKLE CELL DISEASE CONTRIBUTES TO THE RELEASE OF NEUTROPHIL EXTRACELLULAR TRAPS
EHA Learning Center, Kristof Van Avondt, 181742
DEPTH OF RESPONSE AS SURROGATE MARKER FOR PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS TREATED WITH VMP AND RD: GEM2010MAS65
EHA Learning Center, María-Victoria Mateos, 181696
DISEASE CHARACTERISTICS AND SURVIVAL AFTER 3RD RECURRENCE OF CLASSICAL HODGKIN LYMPHOMA: AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP
EHA Learning Center, Paul J Bröckelmann, 181701
LOSS OF RAF KINASE INHIBITOR PROTEIN IS INVOLVED IN MYELOMONOCYTIC LINEAGE COMMITMENT AND AGGRAVATES THE DEVELOPMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN A MURINE IN-VIVO MODEL
EHA Learning Center, Veronica Caraffini, 181706
ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10 -YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV
EHA Learning Center, R Hehlmann, 181711
A MONOALLELIC LOSS-OF-FUNCTION MUTATION IN THE THROMBOPOIETIN (THPO) GENE IS RESPONSIBLE FOR A NEW FORM OF INHERITED THROMBOCYTOPENIA (IT)
EHA Learning Center, Patrizia Noris, 181720
THERAPEUTIC TARGETING OF ONCOGENIC MYB ACTIVITY IN T-ALL
EHA Learning Center, Tim Pieters, 181725
COMPARATIVE ANALYSIS OF PREDICTIVE MODELS FOR THROMBOEMBOLIC EVENTS IN LYMPHOMA PATIENTS
EHA Learning Center, Darko Antic, 181730
MESENCHYMAL STROMAL CELLS STIMULATE THE PROLIFERATION AND IL-22 PRODUCTION BY TYPE 3 INNATE LYMPHOID CELLS
EHA Learning Center, Vera van Hoeven, 181735
HEREDITARY XEROCYTOSIS: CLINICAL AND BIOLOGICAL PRESENTATION AT DIAGNOSIS IN A RETROSPECTIVE SERIES OF 103 PATIENTS
EHA Learning Center, loic garcon, 181740
DEEP AND DURABLE RESPONSES WITH WEEKLY IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP OF PATIENTS WHO DID NOT UNDERGO SCT
EHA Learning Center, Shaji K Kumar, 181695
EARLY CHEMOTHERAPY INTENSIFICATION WITH ESCALATED BEACOPP IN ADVANCED-STAGE HODGKIN LYMPHOMA WITH A POSITIVE INTERIM PET-CT AFTER 2 ABVD CYCLES: LONG-TERM RESULTS OF THE GITIL/FIL HD 0607 TRIAL
EHA Learning Center, Andrea Gallamini, 181700
EFFECTIVENESS OF LSD1 INHIBITION FOR THE TREATMENT OF MPN
EHA Learning Center, Jonas Jutzi, 181705
INITIAL REDUCTION OF THERAPY BEFORE COMPLETE WITHDRAWAL IMPROVES THE CHANCE OF SUCCESSFUL TREATMENT DISCONTINUATION IN CHRONIC MYELOID LEUKAEMIA (CML): YEAR 2 RESULTS IN THE BRITISH DESTINY STUDY
EHA Learning Center, Richard Clark, 181710
NUCLEOSOME BINDING PROTEIN HMGN1 BLOCKS MYELOID DIFFERENTIATION AND PROMOTES CLONAL DOMINANCE VIA ABERRANT HISTONE ACETYLATION
EHA Learning Center, Lucia Cabal-Hierro, 181715
NOVEL PERSPECTIVES IN GENOTYPE-PHENOTYPE CORRELATIONS IN MYH9-RELATED DISEASE: NO LONGER JUST A MATTER OF HEAD OR TAIL
EHA Learning Center, Carlo Zaninetti, 181719
TNF RECEPTOR 2 IS REQUIRED FOR RIP1-DEPENDENT CELL DEATH IN LEUKEMIA
EHA Learning Center, Júlia Aguadé-Gorgorió, 181724
RISK OF THROMBOSIS IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA: A POPULATION-BASED COHORT STUDY
EHA Learning Center, Anna Maria Birgisdottir, 181729
CD4 T CELLS RECOGNIZING MISMATCHED HLA-DP AFTER ALLOGENEIC STEM CELL TRANSPLANTATION SHOW TISSUE SPECIFIC REACTIVITIES
EHA Learning Center, Peter Balen, 181734
STEM CELL TRANSPLANTATION IN PYRUVATE KINASE DEFICIENCY
EHA Learning Center, Stephanie van Straaten, 181739
QUADRUPLET VS SEQUENTIAL TRIPLET INDUCTION THERAPY FOR MYELOMA PATIENTS: RESULTS OF THE MYELOMA XI STUDY.
EHA Learning Center, Charlotte Pawlyn, 181694
NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE MULTICOHORT MULTICENTER PHASE 2 CHECKMATE 205 TRIAL
EHA Learning Center, Andreas Engert, 181699
YOU DON'T KNOW JAK: A PROGRAMMED RIBOSOMAL FRAMESHIFTING DEFECT POTENTIATES THE TRANSFORMING ACTIVITY OF THE JAK2-V617F MUTATION
EHA Learning Center, Sergey SULIMA, 181704
DASATINIB IN CHILDREN AND ADOLESCENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) FROM A PHASE 2 TRIAL
EHA Learning Center, C.M. Zwaan, 181709
ETO2-GLIS2 RECRUITS ETO2/ERG COMPLEX AT SUPER-ENHANCERS TO CONTROL TRANSCRIPTION AND DRIVE LEUKEMIC PROPERTIES IN PEDIATRIC ACUTE MEGAKARYOBLASTIC LEUKEMIA
EHA Learning Center, Cecile Thirant, 181714
THE COMBINATION OF ORAL ALL-TRANS RETINOIC ACID AND DANAZOL VS DANAZOL AS SECOND-LINE TREATMENT IN ADULT IMMUNE THROMBOCYTOPENIA: A MULTICENTRE, RANDOMIZED, OPEN-LABEL TRIAL
EHA Learning Center, Xiao-Hui Zhang, 181718
THE YING AND YANG OF JAK SIGNALING : LOSS OF USP9X BUFFERS JAK SIGNALING AND ENHANCES SURVIVAL OF CRLF2-JAK-STAT EXPRESSING B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA.
EHA Learning Center, Omer Schwartzman, 181723
ASSESSING THE RISK-BENEFIT OF ANTICOAGULANTS IN ELDERLY PATIENTS WITH CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM: A POPULATION BASED STUDY
EHA Learning Center, Alejandro Lazo-Langner, 181728
CYTOSOLIC NUCLEIC ACID SENSORS PROMOTE INTESTINAL EPITHELIALINTEGRITY DURING ACUTE TISSUE DAMAGE AND PROTECT FROM GRAFT-VERSUS-HOST DISEASE
EHA Learning Center, Hendrik Poeck, 181733
EFFECTS OF AG-348, A PYRUVATE KINASE ACTIVATOR, IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY: UPDATED RESULTS FROM THE DRIVE PK STUDY
EHA Learning Center, Rachael F Grace, 181738
AML Treatment Beyond 3+7
EHA Learning Center, Norbert Vey, 184474
Fertility preservation in pre-pubertal and adolescent males
EHA Learning Center, Rod Mitchell, 184479
Controversies in treating small clots in the leg and in the lung
EHA Learning Center, Sebastian Schellong, 184487
CRISPR/Cas9 genome editing, from mechanism to therapy
EHA Learning Center, Jacob Corn, 184491
Fertility Preservation In Female Patients
EHA Learning Center, Marie-Madeline Dolmans, 184478
Targeting Mutated FLT3
EHA Learning Center, Mark Levis, 184473
What patients expect from hematologists
EHA Learning Center, A Plate, 184477
Novel aspects in the diagnostic management of deep vein thrombosis and pulmonary embolism
EHA Learning Center, Menno Huisman, 184486
Towards clinical translation of targeted gene editing in human hematopoietic stem cells
EHA Learning Center, Luigi Naldini, 184490
France-Belgium-Switzerland: The GRAALL Intergroup
EHA Learning Center, Herve Dombret, 184481
Molecular Diagnostics In AML
EHA Learning Center, Lars Bullinger, 184472
The effects of chemotherapy and radiotherapy on reproduction
EHA Learning Center, William Hamish Wallace, 184476
Major results and future approaches of Italian ALL study groups
EHA Learning Center, Sabina Chiaretti, 184480
Cross-talk between inflammation and coagulation
EHA Learning Center, Thomas Renné, 184485
Circulating tumor DNA in Non-Hodgkin lymphoma: Clinical and future research applications
EHA Learning Center, Mark Roschewski, 184470
How to treat CML in 2017
EHA Learning Center, Andreas Hochhaus, 184454
GVL And GVHD Differences And Similarities
EHA Learning Center, Fred Falkenburg, 184458
Neurological complications of sickle cell disease
EHA Learning Center, Fenalla Kirkham, 184462
Rare bleeding disorders - Diagnosis and treatment
EHA Learning Center, Gili Kenet, 184466
Interim-PET as a valid biomarker for early response in malignant lymphoma; when to perform and how to assess
EHA Learning Center, Josee Zijlstra, 184469
Do we still need bone marrow biopsies?
EHA Learning Center, Tarec El-Galaly, 184468
Molecular work up and monitoring of CML patients
EHA Learning Center, NCP Cross, 184453
The Role Of Intestinal Flora In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
EHA Learning Center, Marcel van den Brink, 184457
Iron Chelation In Hemoglobinopathies
EHA Learning Center, Vip , 184461
Diagnosis and management of DIC and primary hyperfibrinolysis
EHA Learning Center, Alessandro Squizzato, 184465
Introduction EHA LyG
EHA Learning Center, M.J. Kersten, 184467
Novel approaches to eradicate CML stem cells
EHA Learning Center, Mhairi Copland, 184452
GvHD Prophylaxis And Treatment, New Modalities
EHA Learning Center, Robert Zeiser, 184456
Genome editing in hemoglobinopathies
EHA Learning Center, Mitch Weiss, 184460
Biological and clinical relevance of fibrin clot structure
EHA Learning Center, Nicola Mutch, 184464
Fertility preservation in females
EHA Learning Center, Marie-Madeline Dolmans, 192906
MANAGEMENT AND OUTCOME OF ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED AT THE “SAPIENZA” UNIVERSITY BETWEEN 1996 AND 2016
EHA Learning Center, Sabina Chiaretti, 181453
H3K27ME3 LEVEL ON THE HIST1 CLUSTER: A POWERFUL EPIGENETIC BIOMARKER THAT STRATIFIES TWO GROUPS OF NPM1-MUTATED AML DIFFERING IN THEIR OUTCOME AND EXPRESSION PROFILE
EHA Learning Center, Sylvain garciaz, 181470